GLP-1 vs Bariatric Surgery
Bariatric surgery produces larger and more durable weight loss but is irreversible and surgical. GLP-1 therapy is reversible, non-surgical, and now closes much of the historical gap, especially with tirzepatide-class molecules.
GLP-1 therapy is the provider-reviewed first-line for most candidates and avoids surgical risk.
Bariatric surgery is appropriate when BMI thresholds and comorbidity burden warrant surgical intervention and the candidate accepts permanence.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Can GLP-1 be used after surgery?
Yes — provider-reviewed adjunctive use is common for incomplete response or regain.
Is surgery still necessary?
For some candidates yes; for many, modern GLP-1 therapy is now sufficient.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment